Related Experiment Video
Updated: Jan 30, 2026

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
Long-Term Clinical and Hemodynamic Outcomes of Transcatheter Mitral Valve Replacement
Nicolas Groshenry1, Gaspard Suc2, Jules Mesnier2
1Cardiology Department, Bichat Claude Bernard Hospital, Public, Paris, France; Université Paris City, Paris, France.
Insights
Transcatheter mitral valve replacement (TMVR) using balloon-expandable aortic prostheses shows favorable long-term clinical and hemodynamic outcomes. This study confirms acceptable durability with low rates of severe structural valve deterioration and valve failure.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Long-term outcomes of transcatheter mitral valve replacement (TMVR) using balloon-expandable aortic prostheses are not well-established.
- Uncertainty exists regarding the durability and clinical efficacy of TMVR in diverse patient populations.
Purpose of the Study:
- To evaluate the long-term clinical and hemodynamic outcomes of TMVR.
- To assess the durability, structural valve deterioration (SVD), and TMVR failure rates.
- To compare outcomes across different TMVR implantation scenarios (valve-in-valve, valve-in-ring, valve-in-mitral annular calcification).
Main Methods:
- A retrospective analysis of 200 patients undergoing TMVR with balloon-expandable transcatheter heart valves, primarily via a trans-septal approach.
- Primary outcome: composite of death or mitral reintervention. Secondary outcomes: mortality, hemodynamics, recurrent mitral regurgitation, SVD, and TMVR failure.
- Median follow-up of 3.2 years.
Main Results:
- Freedom from death or reintervention at 8 years was 20%. Outcomes were worse in valve-in-ring and valve-in-mitral annular calcification compared to valve-in-valve (P < 0.01).
- Mean gradient increased slightly over time, and effective orifice area decreased modestly.
- Severe SVD occurred in 7% of patients, and TMVR failure in 10%.
Conclusions:
- TMVR with balloon-expandable aortic prostheses demonstrates favorable long-term clinical and hemodynamic results.
- The procedure offers acceptable durability with low rates of severe structural valve deterioration and valve failure.
- TMVR is a viable option for mitral valve replacement, though outcomes vary by implantation context.
Background:
Long-term outcomes of transcatheter mitral valve replacement (TMVR) with balloon-expandable aortic prostheses remain uncertain.
Objectives:
The aim of this study was to evaluate long-term clinical and hemodynamic outcomes after TMVR.
Methods:
All patients undergoing TMVR at the authors' center were included. Balloon-expandable transcatheter heart valves were implanted in all cases, usually using a trans-septal approach. The primary outcome was a composite of death or mitral reintervention (surgical or transcatheter replacement or transplantation). Secondary outcomes included mortality, hemodynamic changes, recurrent mitral regurgitation, structural valve deterioration (SVD), and TMVR failure.
Results:
A total of 200 patients underwent TMVR: 60.5% (121 of 200) valve-in-valve, 22.5% (45 of 200) valve-in-ring, and 17% (34 of 200) valve-in-mitral annular calcification. The median age was 70 years (Q1-Q3: 52-80 years), and 67% were women (134 of 200). Median follow-up was 3.2 years (Q1-Q3: 1.2-6.8 years). Freedom from death or reintervention at 1, 5, and 8 years was 82% (95% CI: 77%-88%), 48% (95% CI: 40%-56%), and 20% (95% CI: 11%-29%), respectively, with worse outcomes in valve-in-ring and valve-in-mitral annular calcification compared with valve-in-valve (P < 0.01). Mean gradient increased slightly over time (+0.25 ± 0.07 mm Hg/y; P < 0.01), with a modest decrease in effective orifice area (-0.04 cm2/y; P < 0.01). Significant recurrent mitral regurgitation occurred in 5.5% of patients (11 of 200). Seven percent (14 of 200) developed severe SVD after 5.3 (Q1-Q3: 3.5-7.4 years), and 10% (20 of 200) developed TMVR failure after 4.4 (Q1-Q3: 1.8-6.7 years).
Conclusions:
TMVR with balloon-expandable aortic prostheses provides favorable long-term outcomes and acceptable durability, with low rates of severe SVD and valve failure.
More Related Videos
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse III: Nursing Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Predicting Reaction Outcomes

